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In the previous issue of Arthritis Research & Th  erapy
Charpin and colleagues present French results from an 
interesting cohort of 21 hepatitis B virus (HBV) carriers 
with active rheumatoid arthritis or spondyloarthropathy 
being treated with antibodies to TNF [1]. What do we 
know about anti-TNF therapy in patients who have 
recovered from HBV infection? Hepatology has provided 
knowledge on HBV infection and antivirals have made 
hepatitis a potentially well-treatable disease since three 
decades ago [2]. For the past couple of decades, mono-
clonal antibodies against TNF have been available, 
revo  lu  tionizing antirheumatic therapy [3]. Together with 
immunological progress, however, has come clinical 
complexity. For a rheumatologist encountering a patient 
with severe and active rheumatoid arthritis or spondylo-
arthropathy who is also an HBV carrier, hepatitis is 
regarded as a signiﬁ  cant comorbidity. Th  e  rheumatologist 
is trained not to rest until the inﬂ  ammatory disease has 
gone into remission; to achieve this target, he will 
prescribe all disease-modifying antirheumatic drugs 
(DMARDs), including anti-TNFs. Now a diﬃ   cult question 
arises: how to safely achieve complete remission. 
Methotrexate, the cornerstone of our best disease 
modify  ing regimens, is contraindicated in liver disease.
HBV, a DNA virus transmitted percutaneously, sexually, 
and perinatally,  aﬀ   ects up to  400 million people 
worldwide. HBV infection accounts for up to 5,000 deaths 
in the United States each year and 1 million deaths 
worldwide from cirrhosis, liver failure, and hepatocellular 
carcinoma. Important viral proteins include an envelope 
protein, hepatitis B surface antigen (HBsAg), a structural 
nucleocapsid  core protein, hepatitis B core antigen 
(HBcAg), and a soluble nucleocapsid protein, hepatitis B 
e antigen (HBeAg). Serum HBsAg is a marker of HBV 
infection, and antibodies against HBsAg signify recovery. 
Serum HBeAg is a marker of active viral replication and 
may be accompanied by serum levels of HBV DNA that 
are 100,000 to 1,000,000 IU per milliliter or higher. 
Eradication of HBV infection is diﬃ   cult as long-enduring, 
covalently closed circular DNA (cccDNA)  becomes 
established in hepatocytic nuclei from where HBV DNA 
becomes integrated into the host genome. Th   e study by 
Charpin and colleagues included 58 patients with 
serologically cured HBV infection - that is, HBsAg-
negative plus anti-HBc-positive patients - and of these, 
24 had been treated with anti-TNFs for rheumatoid 
arthritis or spondylitis. Additionally, three were lost due 
to withdrawn consent (n  =  1), HBV-unrelated death 
(n = 1) and being lost from follow-up (n = 1). Finally, 21 
HBV carriers being treated with anti-TNFs were 
included: 3 being treated with adalimumab, 14 with 
etanercept, and 4 with inﬂ  iximab.
Abstract
Over the past decades, more eff  ective and less 
toxic biologicals have revolutionized rheumatology 
therapy in our battle against the autoimmune 
chronic infl  ammation of rheumatoid arthritis and 
spondyloarthropathy. But what about for patients who 
have previously had an infection of the liver? Prior 
hepatitis B virus infection clearly presents a challenge 
for clinicians. In a study by Charpin and colleagues of 
21 patients whose hepatitis B virus serology suggested 
carrier status, anti-TNF treatment appeared to be safe 
during a limited follow-up period of 3 years. Studies are 
needed with longer follow-up, particularly in patients 
with low antibody titres (antiHBc). In the 3-year period, 
however, about 30% of the patients developed 
signifi  cant lowering of antibody titres, which may 
become relevant during long-term follow-up. Charpin 
and colleagues are the fi  rst to reveal promising data 
on the relative safety of anti-TNFs in a small series of 
hepatitis B carriers for up to 3 years.
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HBV infections  occur during adolescence and early 
adulthood due to sexual activity, intravenous drug use, 
and occupational exposure. In immunocompetent adoles-
cents and adults, a strong cellular immune response to 
‘foreign’ HBV proteins expressed by hepatocytes results 
in clinically apparent acute hepatitis, which in 99% of 
infected people aﬀ  ects clearance of the infection [4,5]. 
Th  e progression of liver disease after HBV infection is 
fostered by active virus replication, indicated by a serum 
HBV DNA level of 1,000 to 10,000 IU per milliliter. In 
such cases anti-TNFs are contraindicated but antiviral 
regimens should be considered. A serum HBV DNA level 
<1,000 IU per milliliter and normal alanine amino-
transferase (ALT) levels are considered to be indicators of 
inactive carriers with only a low risk of clinical 
progression [6]; rarely, reactivation can occur spontan-
eously or with immunosuppression [7-9]. As clinical and 
histological improvement accompanies reduc  tions  in 
HBV replica  tion, interventions reducing HBV replication 
are indicated in such cases to limit progressive liver 
disease. When virus infection has been overcome, 
immuno  suppression is relatively contra  indicated. Practi-
cally, outcomes of HBV infection evolve only over 
decades. Clinical trials, as well as Charpin and colleagues’ 
study, are limited to only several years, rarely up to 
5  years. Surrogate, achievable endpoints  are  there fore 
used, including serologic (HBsAg recurrence, represent-
ing recurrent hepatitis versus ade  quate antiHBc levels, 
suggesting carrier state), virologic (log10 reduction versus 
increase in the HBV DNA level, or suppression versus 
expression of HBV DNA to an (un)detectable level (<10 
to 100 IU per millilitre)), as well as a commonly used 
biochemical parameter (normaliza  tion versus increase 
above the upper normal limit of the serum ALT level).
Over the past decades, more eﬀ  ective and less toxic 
biologicals have revolutionized rheumatology therapy in 
our battle against the chronic autoimmune inﬂ  ammation 
of rheumatoid arthritis and spondyloarthropathy. Unmet 
needs are adequate access and long-term safety issues 
regarding tumor and infection risk. What if one has 
previously had an infection of the liver? Patients who 
have had a prior HBV infection clearly present a 
challenge for clinicians. If HBV serology suggests a 
carrier state, then anti-TNF appears to be safe during a 
limited follow-up period of 3 years. Studies are needed 
with longer follow-up, particularly in patients with low 
antibody titres (anti-HBc). In a 3-year period, however, 
about 30% of the French patients in the study by Charpin 
and colleagues developed signiﬁ  cant lowering of antibody 
titres, which may become relevant during long-term 
follow-up. Charpin and colleagues are the ﬁ  rst to reveal 
promising data on the relative safety of anti-TNFs in a 
small series of HBV carriers over a period of 3 years.
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